Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Sarepta Therapeutics (SRPT) has drawn attention after a challenging stretch for shareholders, with the stock showing negative total returns over the past year and multi year period, as well as a pullback over the past month and past three months.
See our latest analysis for Sarepta Therapeutics.
At a share price of $16.71, Sarepta’s 1 day share price return of 2.96% comes after a 30 day share price return decline of 15.31% and a 1 year total shareholder return loss of 83.78%. This suggests sentiment has weakened rather than built momentum recently.
If Sarepta’s recent swings have you rethinking where you look for growth, this could be a good moment to scan our screener of 32 healthcare AI stocks for fresh ideas.
With the share price at $16.71, an estimated intrinsic value gap of around 78% and a discount of about 22% to the average analyst target, you have to ask: is this a reset buying opportunity, or is the market already factoring in any future growth?
The most widely followed narrative currently pegs Sarepta’s fair value at about $21.43, compared with the last close at $16.71. This frames a clear valuation gap for investors to interrogate.
The analysts have a consensus price target of $23.96 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $80.0, and the most bearish reporting a price target of just $5.0.
Want to understand what kind of revenue reset, margin lift, and future earnings multiple need to line up to support that $21 plus fair value? The core narrative leans on a sharp swing from losses to profit, paired with a richer future valuation multiple than many mature biotechs. If you are curious how those ingredients combine to justify Sarepta’s current discount and still argue for upside, the full story lays out the specific assumptions that drive that conclusion.
Result: Fair Value of $21.43 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, there are still real swing factors here, including the Elevidys safety overhang and the revived patent suit, which could challenge the current valuation story.
Find out about the key risks to this Sarepta Therapeutics narrative.